Comparing two HIV treatments for people with overweight or obesity
Treatments studied
Part of Hormones & metabolism, Immune system & allergy, Infections clinical trials.
This trial compares two different daily pill combinations for people newly starting HIV treatment who are overweight or have obesity. It aims to see which one works better for controlling the virus and managing weight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older
- You must have been diagnosed with HIV and never taken HIV medications before
- Your viral load must be 1000 copies/mL or higher
- Your body mass index (BMI) must be 25 or higher, and your body fat percentage must be greater than 20
- Your kidney function must be at least 60 mL/min, and your liver tests must be within certain limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a diabetes medicine, can improve weight and metabolism in people with HIV who take dolutegravir and have a high body mass index (BMI). It may help reduce weight gain linked to HIV treatment.
This study tests whether switching your HIV medication to a combination called DOR/3TC/TDF can help with weight changes that started after taking another type of HIV drug (integrase inhibitor). It is for people who have gained weight unintentionally and want to see if a different medication helps manage it.
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This trial tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a three-drug regimen (darunavir/cobicistat plus tenofovir alafenamide/emtricitabine) in men whose HIV is already suppressed. The goal is to find a simpler, effective option that may have fewer side effects.
This study tests a newer HIV medication, B/F/TAF, as a first-line treatment. It compares B/F/TAF with older combinations (TDF+3TC+EFV or DTG/3TC) to see how well it works for people who have never taken HIV meds.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.